- Home
- EYEN
EYEN
Eyenovia Inc.
as 07-26-2024 4:00pm EST
Eyenovia Inc is a clinical stage ophthalmic company developing a pipeline of therapeutics based on its propriety array print (MAP) platform technology. It aims to achieve clinical microdosing of next-generation formulations of novel and existing ophthalmic pharmaceutical agents using its high-precision targeted ocular delivery system, branded the Opejet, which has the potential to replace conventional eye dropper delivery and improve safety, tolerability, patient compliance and topical delivery success for ophthalmic eye treatments. Using its proprietary delivery technology, Eyenovia is developing the next generation of smart ophthalmic therapies which target new indications or new combinations.
| Founded: | 2014 | Country: | United States |
| Employees: | N/A | City: | NEW YORK |
| Market Cap: | 38.3M | IPO Year: | 2018 |
| Target Price: | $10.00 | AVG Volume (30 days): | 1.3M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.73 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.50 - $2.57 | Next Earning Date: | 08-08-2024 |
| Revenue: | $8,780 | Revenue Growth: | N/A |
| Revenue Growth (this year): | 107320.13% | Revenue Growth (next year): | 199.98% |
Stock Insider Trading Activity of Eyenovia Inc. (EYEN)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Grant Stuart M. | EYEN | 10% Owner | Jul 2 '24 | Buy | $0.66 | 1,515,151 | $999,999.66 | 10,914,153 | SEC Form 4 |
| Grant Stuart M. | EYEN | 10% Owner | Mar 28 '24 | Buy | $0.98 | 100,000 | $98,000.00 | 5,430,715 | SEC Form 4 |
| Grant Stuart M. | EYEN | 10% Owner | Mar 19 '24 | Buy | $1.23 | 50,000 | $61,500.00 | 5,330,715 | SEC Form 4 |
| Grant Stuart M. | EYEN | 10% Owner | Mar 8 '24 | Buy | $1.58 | 10,717 | $16,911.43 | 5,280,715 | SEC Form 4 |
Latest Eyenovia Inc. News
EYEN Breaking Stock News: Dive into EYEN Ticker-Specific Updates for Smart Investing
GlobeNewswire
4 days ago
Eyenovia and Senju Pharmaceutical Co., Ltd. Sign Collaboration Agreement for Potential New Treatment for Chronic Dry Eye Disease
Simply Wall St.
19 days ago
Eyenovia Insiders Enjoying US$200k Appreciation On US$1.34m Investment
MT Newswires
25 days ago
NovaBay Pharmaceuticals, Eyenovia Begin Co-Promotion Deal Activities
Business Wire
a month ago
NovaBay Pharmaceuticals and Eyenovia Commence Co-Promotion Activities
GlobeNewswire
a month ago
Eyenovia Announces Pricing of $5M Registered Direct Offering
Zacks
2 months ago
All You Need to Know About Eyenovia (EYEN) Rating Upgrade to Buy
GuruFocus.com
2 months ago
Eyenovia Inc (EYEN) (Q1 2024) Earnings Call Transcript Highlights: Navigating Challenges and ...
GlobeNewswire
2 months ago
Eyenovia Reports First Quarter 2024 Financial Results and Provides Updates on its Myopia Phase III Program and its Two FDA Approved Commercial Products, Mydcombi and Clobetasol
Compare EYEN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "EYEN Eyenovia Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.